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Abstract: In the absence of lymphatics, fluid and solutes such as amyloid-β (Aβ) are eliminated from
the brain along basement membranes in the walls of cerebral capillaries and arteries—the Intramural
Peri-Arterial Drainage (IPAD) pathway. IPAD fails with age and insoluble Aβ is deposited as plaques
in the brain and in IPAD pathways as cerebral amyloid angiopathy (CAA); fluid accumulates in
the white matter as reflected by hyperintensities (WMH) on MRI. Within the brain, fluid uptake by
astrocytes is regulated by aquaporin 4 (AQP4). We test the hypothesis that expression of astrocytic
AQP4 increases in grey matter and decreases in white matter with onset of CAA. AQP4 expression
was quantitated by immunocytochemistry and confocal microscopy in post-mortem occipital grey
and white matter from young and old non-demented human brains, in CAA and in WMH. Results:
AQP4 expression tended to increase with normal ageing but AQP4 expression in severe CAA was
significantly reduced when compared to moderate CAA (p = 0.018). AQP4 expression tended to
decline in the white matter with CAA and WMH, both of which are associated with impaired IPAD.
Adjusting the level of AQP4 activity may be a valid therapeutic target for restoring homoeostasis in
the brain as IPAD fails with age and CAA.
Keywords: aquaporin 4; cerebral amyloid angiopathy; white matter hyperintensities; grey matter;
white matter
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1. Introduction
Accumulations of amyloid-β (Aβ) and tau proteins in the brain are well-recognised pathological
features of Alzheimer’s disease [1]. Fluid also accumulates in the brain with age and Alzheimer’s
disease as seen on MRI as dilated perivascular spaces in the white matter and by white matter
hyperintensities (WMH). Why fluid accumulates in these sites is still under debate, but advancing age
and CAA correlate with dilated perivascular spaces and with WMH [2]. Accumulation of Aβ and of
fluid in the brain suggests that there may be loss of homoeostasis in Alzheimer’s disease due to failure
of elimination of these components and other solutes from the brain.
In the absence of lymphatic vessels in the brain parenchyma, fluid and solutes drain from the brain
to cervical lymph nodes along basement membranes in the walls of cerebral capillaries and arteries [3].
The route of drainage is along basement membranes in the walls of capillaries and, most noticeably,
along basement membranes of smooth muscle cells in the tunica media of cerebral arteries [4,5]; it has
therefore been named the Intramural Peri-Arterial Drainage (IPAD) pathway [6]. As arteries age,
the efficiency of IPAD for the elimination of soluble Aβ from the brain is impaired and even more
reduced by the deposition of insoluble Aβ in basement membranes of the IPAD pathways in cerebral
amyloid angiopathy (CAA) [7,8].
In this paper, we approach the accumulation of fluid in the white matter in Alzheimer’s disease
and CAA from a different angle. We examine how levels of expression of Aquaporin 4 (AQP4)
associated with astrocytes in the brain change in relation to the patient’s age and the presence of CAA,
as well as WMH. AQP4 appears to be involved in the removal of oedema fluid from the brain in a
variety of disorders and enhancing AQP4 expression could be a therapeutic strategy for reducing
dilated perivascular spaces and WMH associated with advancing age and Alzheimer’s disease.
Aquaporin 4 (AQP4) is the predominant water channel in mammalian brain expressed in astrocyte
endfeet bordering the ventricles, subarachnoid space, blood vessels, glial processes of the granule
cell layer in the cerebellum [9] and to a lesser extent in adluminal and abluminal endothelial cell
membranes [10,11]. In humans and mice, the distribution of AQP4 is predominantly localised to
astrocytic endfeet adjacent to cerebral vasculature. However, in humans a higher proportion of AQP4
is also expressed in astrocytic cell membranes facing the parenchyma [12]. The expression of AQP4 is
influenced by anatomical location [9,13–15] and by disease. For example, in experimental models of
ischaemia or in the deep white matter of post stroke dementia, there is a redistribution of AQP4 from
astrocyte end feet to the astrocytic cell bodies [16,17].
A key function of AQP4 appears to be the regulation of water transport across astrocytic cell
membranes. In diseases that alter brain water homeostasis such as brain tumours [18,19], stroke [20,21]
and traumatic brain injury [22], AQP4 expression is increased. This is thought to be associated with
oedema resolution [23]. Mice deficient in AQP4 appear to be less affected by cytotoxic oedema [24] but
more susceptible to vasogenic and hydrocephalic oedema [25,26].
White matter hyperintensities (WMH) [2] and abnormalities in fluid homeostasis in the white
matter are frequent radiological observations in neurodegenerative diseases. White matter is highly
susceptible to oedema after acute injury to the central nervous system (CNS) [27–29] and WMH are a
common finding on computer tomography (CT) or magnetic resonance imaging (MRI) in the elderly,
in stroke, dementia and cerebral amyloid angiopathy (CAA) [30]. Dilated perivascular spaces visible
on MRI have been described in the white matter of patients with Alzheimer’s disease (AD) or CAA [31].
Previous studies have shown that AQP4 expression is altered in mouse models of AD and humans with
AD [32–34] and have indicated a link between AQP4 expression and amyloid burden [35]. A recent
study showed elevated expression of AQP4 in the grey matter from autopsied temporal lobes from
eight patients with Alzheimer’s disease (AD) [36]. However, it is not clear if alterations in AQP4
expression in the grey matter are accompanied by a similar pattern in the expression of AQP4 in the
white matter or whether AQP4 expression is linked to severity of CAA.
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Due to the dynamic role that astrocytes play in neurodegenerative diseases [37,38], in this study
we analysed how the expression of AQP4 in the white and grey matter changes in the occipital cortex
obtained from young and old non-demented humans. We then investigated whether these changes
were altered in neurodegenerative diseases by comparing AQP4 expression in (a) the white matter and
grey matter of occipital cortex obtained from human cases of CAA with (b) white matter obtained from
cases with WMH and (c) white and grey matter from non-demented age matched controls. Finally,
we investigated how the severity of neurodegenerative disease affects AQP4 expression by comparing
white and grey matter of occipital cortex obtained from human cases of moderate or severe CAA.
Dilated perivascular spaces have not been observed in the cerebral cortex, even when there
is pathology present [39] but they are common in the white matter of patients with CAA [31,40].
Considering the role of AQP4 as a water channel and that WMH and dilated perivascular spaces reflect
an excess of fluid in the parenchyma, here we test the hypothesis that expression of AQP4 increases in
the grey matter and decreases in the white matter with onset of CAA when compared to age matched
controls. As the physiological capacity of AQP4 for clearing fluid is exceeded, we suggest that the
expression of AQP4 is decreased in white matter with WMH, compared to the white matter of young
and old non-demented cases.
2. Results
2.1. The Pattern of Immunostaining for AQP4 Is Different in the Grey Compared to White Matter and Changes
with Age and with Severity of CAA
In the grey matter from young brains, immunostaining revealed individual AQP4 positive arborized
astrocytes scattered in the cortex (Figure 1a), particularly concentrated at the grey-white matter border.
Fewer AQP4 positive astrocytes were observed in the white matter (Figure 1e). Glial fibrillary acidic protein
(GFAP) immunostaining revealed highly arborized astrocytes surrounding the profiles of blood vessels of
all sizes (Figure 2a,e). In brains from old non-demented controls, immunostaining of AQP4 appeared
fibrillary or granular and no longer distinguished individual astrocytes. The AQP4 immunoreactivity
appeared to reveal the profiles of blood vessels (Figure 1b,f). GFAP immunostaining was very intense,
particularly in fine processes and cell bodies (Figure 2b,f). In grey matter from brains with moderate CAA,
immunostaining revealed highly arborized AQP4 positive astrocytes, with staining of both cell bodies and
processes. There was no apparent relationship with the profiles of blood vessels and a reduction of AQP4
immunoreactivity at the grey–white matter border was observed. Only punctate sparse staining was
observed in the white matter (Figure 1c,g). GFAP immunostaining showed the profile of many astrocyte
processes and a perivascular location in the grey matter. In the white matter, the high density of stained
processes observed with AQP4 immunostaining was not present with GFAP immunostaining and the
staining with GFAP was mainly perivascular (Figure 2c,g).
In brains with severe CAA, the immunostaining for AQP4 was sparse and weak (Figure 1d,h) and
mainly in a perivascular location in the grey matter. In contrast, GFAP immunostaining was intense
and localised to perivascular locations of both grey and white matter (Figure 2d,h). In white matter
hyperintensities the immunostaining for AQP4 was very weak in comparison to the strong GFAP
staining (Figures 1i and 2i).
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2.2. Double Immunostaining
Double immunostaining in young brains revealed the association of AQP4 with GFAP positive
astrocyte cell processes in discrete areas (Figure 3(a1–a3)), particularly near collagen IV positive
blood vessels in the grey matter (Figure 3(c1–c3)). In the white matter of young brains the AQP4
was punctate and faint with a small degree of coexpression with GFAP and perivascular collagen
IV (Figure 3(b1–b3,d1–d3)). In old control brains, double immunostaining revealed a more diffuse
distribution of AQP4 (Figure 3(e2)) in the grey matter. Very little AQP4 was closely associated with
GFAP positive cell bodies (Figure 3(e3)) and blood vessels in the grey matter (Figure 3(g1–g3)). In the
white matter of old non demented brains, there was a close association of AQP4 with GFAP and
with collagen IV associated with blood vessels (Figure 3(f1–f3,h1–h3)). In moderate CAA, there was
little or no co-expression observed between AQP4 and GFAP in both grey (Figure 4(a1–a3)) and
white matter (Figure 4(b1–b3)) and immunostaining for collagen IV demonstrated some perivascular
localization of AQP4 (Figure 4(c1–c3,d1–d3)). AQP4 did co-localise with the amyloid deposits that
were mainly observed in the grey matter (Figure 4(e1–e3)). No amyloid deposits were observed
in the white matter (Figure 4(f1–f3)). In severe CAA, the immunostaining for GFAP was far more
intense and occupied all of the field of view (Figure 4(g1–h1)), in comparison to the small perivascular
immunostaining for AQP4. Collagen IV immunostaining confirmed the presence of the weak punctate
AQP4 immunostaining around but not exclusively limited to blood vessels especially in the grey matter
(Figure 4(i3,j3)). The AQP4 staining was arborized and diffuse in the areas of vascular amyloid in both
grey and white matter (Figure 4(k3,l3)).
Figure 1. Pattern of AQP4 immunostaining in the parenchyma of young, non-demented aged control,
CAA and WMH brains. In young brains, individual AQP4 positive arborized astrocytes (arrows)
are scattered in the cortex (a) with faintly stained small cell bodies in the white matter (e). In old
non-demented brains, immunostaining of AQP4 appears granular and outlining processes, no longer
distinguishing individual astrocytes in either grey (b) or white matter. Immunoreactivity in the white
matter appears to outline blood vessels (arrows) (f). In moderate CAA, immunostaining reveals highly
arborized AQP4 positive astrocytes, with staining of both cell bodies and processes in the grey matter
(c). Only punctate sparse staining is observed in the white matter (g). In severe CAA, immunostaining
for AQP4 is sparse and weak in both grey matter (d) and white matter (h) but mainly in a perivascular
location (arrows) in the grey matter (d). In WMH brains, immunostaining of AQP4 is very weak,
with few faintly stained processes (i). Scale bar 100 µm.
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Figure 2. The pattern of immunostaining for GFAP associated with the blood vessels of grey and white
matter. In young brains, GFAP immunostaining reveals highly arborized astrocytes and profiles of
blood vessels of all sizes in both grey and white matter (arrows) (a and e). In old non-demented brains,
the GFAP immunostaining appears intense in the grey matter, highlighting fine processes and cell
bodies (arrow) (b) but granular (arrow) and mostly in perivascular locations in the white matter (f).
In the grey matter of moderate CAA brains, the immunostaining of GFAP shows intensely stained
processes surrounding the vessels (c) but in the white matter is confined to the perivascular locations
(arrows) (g). In severe CAA brains, GFAP immunostaining is intense and localised to the blood vessels
of both grey (arrow) (d) and white matter (arrow) (h) with small cell bodies also present in the white
matter (h). In WMH brains the GFAP immunostaining is relatively intense, highlighting fine processes
and cell bodies in the white matter and surrounding vessels (i). Scale bar 100 µm.
2.3. AQP4 Expression Is Altered with Severity of CAA
The outcome variables percentage area stained for AQP4 in grey and in white matter were
both positively skewed (Figure 5a). No particular pattern emerged from the outliers regarding age
and gender. The outliers in the young and in the old non-demented group seemed to have higher
percentage areas stained for AQP4 in both grey in white matter; however, this is not the case in the two
CAA groups.
Braak stage and disease state were ordinal variables and skewed. Spearman’s rank correlation
coefficient showed that the disease state and Braak stage were significantly related (n = 26, rho = 0.704,
p < 0.001) indicating a positive strong correlation between disease state and Braak stage (Figure 5b).
AQP4 expression was increased in grey and white matter with normal ageing. In the white matter,
AQP4 expression decreased with disease, with the highest expression in old aged controls, followed by
CAA and WMH. In the grey matter, AQP4 expression increased from young to old non-demented,
then peaked at moderate CAA and then decreased in severe CAA (Figure 5c, Table S1a).
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Figure 3. Double immunofluorescence for AQP4 (green) and GFAP (magenta) or collagen IV (blue) in
young and old-demented brains. In grey matter from young brains, AQP4 appears highly arborized
in a perivascular location (arrows c2,c3) with some degree of association with GFAP (a1–a3 and
c1–c3). In white matter from young brains, AQP4 immunostaining is faint, with very small degree
of co-expression with the wide distribution of GFAP-immunostained cells and fine processes (b1–b3)
and with only little relation to collagen IV (arrows) (d1–d3). In the grey matter of old non-demented
brains, AQP4 immunostaining shows a diffuse fibrillary pattern with small cell bodies in comparison
to the larger cell bodies and processes immunostained with GFAP, with almost no association with
GFAP positive astrocytes (e1–e3) and with very sparse perivascular distribution (g1–g3). In the white
matter of old non-demented brains, AQP4 is associated with GFAP positive cell bodies (f1–f3) and
in a perivascular location as shown by co-expression with collagen IV in the wall of the blood vessel
(arrows) (h1–h3).
Although not statistically significant (p = 0.319) the average percentage area stained for AQP4 was
higher in the grey matter (2.21%) than in the white matter (1.13%) in young brains. In contrast, in the
old non-demented brains, this was higher in the white matter (5.01%) when compared to the grey
matter (2.86%), but this difference was also not statistically significant (p = 0.192) (Table S1b). When
compared to young brains, the white matter of old non-demented brains showed a 3.88% increase in
mean percentage area stained for AQP4 (Figure 5c, Table S1(c2)), and 0.48% in terms of the median
difference (Table S1(c1)).
In moderate CAA, the average percentage area stained for AQP4 was higher however not
significant in the grey matter (5.49%) compared to the white matter (2.76%) (p = 0.175, Table S1b) and
higher than the grey matter in old non-demented age matched controls (5.49% vs 2.86%) (p = 0.055)
(Figure 5c, Table S1(c2)). Although not significant (p = 0.895), in severe CAA brains the percentage
area stained for AQP4 was higher in the white matter (2.27%) when compared to the grey matter
(2.09%) (Figure 5c, Table S1b). When compared to moderate CAA, the grey matter in severe CAA
showed a significant decrease in the percentage area stained for AQP4 (2.09% vs 5.49%) (p = 0.018 at 5%
significance level) (Figure 5c, Table S1(c2)), but not significant marginally after adjusting for multiple
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comparisons. The white matter also showed a decrease in the percentage area stained for AQP4 but
this was not significant (2.27% vs 2.76%, p = 0.807) (Table S1(c2)).
Figure 4. Double immunofluorescence for AQP4 (green) with GFAP (magenta), collagen IV (blue) or
Aβ (red) in moderate or severe CAA. In the grey matter of moderate CAA, both AQP4 and GFAP
immunostaining appears intense with AQP4 more diffuse (a1–a3). AQP4 appears in a perivascular
location as shown by the association with collagen IV (c1–c3) but also appears associated with the
presence of Aβ (e1–e3). In the white matter of moderate CAA, AQP4 immunostaining appears fainter
(b1–b3), with some close relation to collagen IV (d1–d3). No Aβ immunostaining was detected in
the white matter (f1–f3). In the grey matter of severe CAA, immunostaining of GFAP appears more
intense than that of AQP4 (g1–g3). Immunostaining of AQP4 (g2) appears reduced when compared
to that seen in the grey matter of moderate CAA (a2) but can be observed in a perivascular location,
as seen by the relation to collagen IV immunostaining (i1–i3). Immunostaining of AQP4 can also
be seen in close proximity to blood vessels laden with Aβ (k1–k3). In the white matter of severe
CAA, the immunostaining of AQP4 appears diffuse with some punctate cell bodies stained and little
perivascular distribution (h1–h3 and j1–j3). Granular AQP4 immunostaining can be seen surrounding
blood vessels containing some Aβ (l1–l3). Scale bar 100 µm.
The univariate linear regression model on percentage area stained for AQP4 in grey matter showed
that disease state and Braak stage were both significantly related to the outcome (p = 0.030 and 0.005
respectively, Table S1d). Disease state remained as a significant factor (p = 0.013) after adjusting for
Braak stage, age and sex. The key adjusted differences amongst the disease states were when moderate
CAA compared to old non-demented controls (p = 0.010, Table S1d) and when compared to severe
CAA (p = 0.013, Table S1e). Braak stage was no longer a statistically significant factor after adjusting
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for the 3 covariates. Regression model without adjusting for age and sex was also developed and the
results were similar to the full model (Table S1d,e). We did not observe any significant results in the
regression models on white matter.
Figure 5. Graphical representation of the data and statistical analyses. (a) all data demonstrating
skeweness; (b) a scatter pot (with identical values stacked) reflecting the relationship between Braak
stage and disease state; (c) graph with the mean (±SE) percentage area of AQP4 immunostaining for
grey and white matter in young, old non-demented, moderate and severe CAA, as well as white matter
hyperintensities. In moderate CAA, the percentage area stained for AQP4 was higher in the grey matter
compared to the white matter and higher than the grey matter in old non-demented age matched
controls (p = 0.055). When compared to moderate CAA, the grey matter in severe CAA showed a
decrease in the percentage area stained for AQP4 (p = 0.018). Significance level is set at 0.0125 by the
Bonferroni method for grey matter due to multiple comparisons.
3. Discussion
This study shows the quantitative differences in the percentage area immunostained for AQP4 in
grey and white matter from young, old non-demented, CAA and WMH brains. We demonstrate that
AQP4 immunostaining in the grey matter of young brains outlines clearly astrocyte cell bodies and
processes. In brains from old, non-demented individuals, the pattern of immunostaining is granular
and in the white matter outlines the profiles of blood vessels. A power calculation was not performed
at the beginning of this study, as the number of eligible brain samples we could access was very limited.
Moreover, we have taken a conservative approach by adjusting the statistical significance level with
the Bonferroni method when comparing the disease states, hence some of our key findings are not
statistically significant.
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In the grey matter of moderate CAA, AQP4 outlines individual cell bodies and processes of
astrocytes. When compared to the grey matter of severe CAA brains, the expression of AQP4 was
higher in the moderate CAA cases compared to age-matched controls, supporting previous reports of
astrogliosis in CAA, where MMP2 positive astrocytes were observed surrounding the CAA-related
haemorrhages [41].
We observed a trend towards increased expression of AQP4 with ageing and in the grey matter
of moderate CAA compared to non-demented age matched controls. In contrast, when analysing
the white matter, the highest expression was observed in the non-demented age matched controls,
followed by CAA and WMH. Our results are in agreement with recent studies that showed an increased
expression of AQP4 with advancing age and in CAA, although these studies did not perform separate
analyses for the grey and white matter [42] and did not include white matter hyperintensities [43].
Individual processes of astrocytes stained by AQP4 were observed only in moderate CAA. Loss of
perivascular AQP4 is associated with increased severity of Aβ plaques [42], and recent work proposes
that the distribution of AQP4 around plaques is associated with formation of a glial net surrounding
the plaque, recruitment of microglia, with a role in the partial protection of nearby neurons from the
deleterious effects of Aβ aggregates [44].
When AQP4 was compared to immunostaining for GFAP, the striking differences were observed
in old non-demented age matched controls and in CAA. In the old non-demented age matched
controls, the main differences between the pattern of immunostaining for AQP4 and GFAP in the grey
matter were that AQP4 immunostaining showed processes and a granular appearance not associated
with blood vessels, whereas GFAP was intensely outlining blood vessels and in very fine processes.
In moderate CAA, the immunostaining for AQP4 was intensely arborized, with no obvious relation to
the blood vessels in either grey or white matter, whereas GFAP was confined mainly to blood vessels.
There was obvious loss of AQP4 immunostaining in both grey and white matter of severe CAA cases
compared to moderate CAA or old non demented cases. In contrast, the immunostaining for GFAP
in severe CAA was similar to that of moderate CAA, with a distribution mainly in a perivascular
location. These results suggest that GFAP indeed reflects a generalised increase in the function of
astrocytes with ageing and with CAA, whereas the water channel AQP4 increases in moderate CAA
but is almost absent in severe CAA. The discrepancy between the patterns of immunostaining for
AQP4 and GFAP was very obvious in cases of WMH. While AQP4 was very faint with only a few
processes immunostained, the GFAP-positive astrocytes had many processes and small cell bodies,
with perivascular immunostaining. This morphological discrepancy may reflect the failed function of
AQP4 to maintain water balance in WMH while astrocytes are upregulated in their function overall.
The phenotype of astrocytes changes with CAA, as reflected by changes in GFAP markers [32].
The double immunofluorescence staining for AQP4 and GFAP or Collagen IV demonstrated
that in the young grey matter AQP4 and GFAP were distributed in a very similar pattern, whereas
in the old non-demented controls there appeared to be more GFAP staining in both grey and white
matter. In young and old non-demented controls, AQP4 was distributed in a perivascular pattern as
demonstrated by collagen IV immunostaining, confirming previous reports [32]. This perivascular
distribution was maintained in moderate CAA, in which AQP4 immunostaining was highly arborized
in the grey matter, but was lost in the grey matter of severe CAA. While we did not perform any
biochemical analyses, our findings are in agreement with previous reports that demonstrated an overall
reduction in the gene expression of AQP4 in severe CAA [32].
Previous studies focused on the elimination of fluid and solutes from the brain have demonstrated
that the major drainage pathway is along basement membranes in the walls of cerebral capillaries and
basement membranes surrounding smooth muscle cells in the tunica media of cerebral arteries. This is
the Intramural Peri-Arterial Drainage (IPAD) pathway that is effectively the drainage route for fluid
and solutes from the brain to cervical lymph nodes [45,46]. Our present results reflect the dynamic
changes that occur within the brain parenchyma with age and CAA by recording the expression
and localization of AQP4 channels with increasing age and CAA. The increased expression of AQP4
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in the grey matter accompanying moderate CAA probably reflects the increased need for reactive
astrocytes to clear excess fluid resulting from interference with fluid drainage that accompanies CAA.
Responses within the brain through expression of AQP4 appear to be lost with advancement of disease
to severe CAA. A clear picture of how the pattern of immunocytochemistry of AQP4 changes in the
grey and white matter in health and disease will advance our knowledge of how best to target AQP4
for rebalancing levels of fluid and solutes in the brain in CAA and Alzheimer’s disease [47].
4. Materials and Methods
4.1. Experimental Subjects
Brain tissue cohort: tissue from younger individuals (≤50 years old) was supplied by the MRC
funded Edinburgh Brain Bank (Ethics REC 16/ES/0044), old (70–96 years old) and CAA (62–99 years
old) tissue was supplied by Newcastle Brain Tissue Resource (Ethics REC 08/H0906/136) and tissue
correlating to WMH (78–91 years old) was supplied by the Cognitive Function Ageing Study (CFAS),
Sheffield (Ethical approval 15/SW/0246) (Table 1). Cases from Newcastle were diagnosed according to
internationally used criteria including neuritic Braak stages [48], Thal amyloid phases [49], CERAD
scores [50], NIA-AA guidelines [51] and McKeith criteria for Lewy body disease [52]; these cases
showed varying degrees of AD pathology with no Lewy Body pathology.
The severity of CAA in the occipital lobe was graded according to the system proposed by
Vonsattel and colleagues [53] which refers to severity of CAA in individual blood vessels: “mild”,
amyloid is restricted to the tunica media without significant destruction of smooth muscle cells;
“moderate”, the tunica media is replaced by amyloid and is thicker than normal; “severe”, extensive
amyloid deposition with focal wall fragmentation or even ‘double barrelling’ of the blood vessel
wall, microaneurysm formation, fibrinoid necrosis and leakage of blood through the blood vessel
wall [54]. To provide a better estimation of the combined severity of CAA across the entire histological
section from the occipital lobe, we scored CAA according to the method described by Love and
colleagues [55]: score 1 refers to scant amyloid-β (Aβ) deposition in the vessel wall, while score 2
refers to some circumferential and score 3 to widespread circumferential Aβ deposition, respectively.
Parenchymal and meningeal CAA are separately scored and scores are added to provide an overall
score. The presence of Aβ deposition in capillary walls (i.e., capillary CAA) is scored as 1 and added to
the sum of parenchymal and meningeal scores. Based on the presence of capillary CAA, CAA can be
classified into type 1 where capillary CAA is present and type 2 which lacks capillary CAA [56]. For
this study, cases with CAA scores [55] below 6 were staged as low/moderate CAA, and cases with
scores of 6 or higher were considered to have severe CAA (see Table 1). Moderate and severe CAA
cases were diagnosed using a staging system which assesses meningeal, parenchymal and capillary
CAA separately [57]. None of these cases was diagnosed with CAA during life.
Cases from the MRC Edinburgh Brain Bank had no neurological disease during life and
no significant neuropathological changes post mortem. We have excluded any cases with
arteriolosclerosis/lipohyalinosis from this cohort. Tissue sampling from formalin-fixed coronal cerebral
slices was guided by post-mortem MRI scans to identify WMH, as previously described [58], and the
lesion/non-lesional status of the sampled blocks confirmed by Luxol fast blue stain for myelin loss and
immunohistochemisty to the microglial marker CD68. All samples were collected and prepared in
accordance with the National Research Ethics Service approved protocols.
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Table 1. Demographics of cases used for this study.
Source Age Sex PM Delay /Hrs Category Braak Stage Thal Phase
Edinburgh 50 M 45 Young
Edinburgh 44 M 47 Young
Edinburgh 21 M 111 Young
Edinburgh 29 M 44 Young
Edinburgh 38 M 49 Young
Edinburgh 49 M 79 Young
Edinburgh 32 M 99 Young
Newcastle 96 F 114 old non-demented 2 3
Newcastle 95 M 21 old non-demented 3 3
Newcastle 83 F 24 old non-demented 1 1
Newcastle 74 M 70 old non-demented 0 0
Newcastle 77 M 46 old non-demented 3 0
Newcastle 89 F 98 old non-demented 3 2
Newcastle 70 M 72 old non-demented 0 1
Newcastle 81 F 31 old non-demented 3 5
Newcastle 76 F 41 old non-demented 2 3
Newcastle 99 F 71 CAA/moderate CAA 6 n/a
Newcastle 63 M 40 CAA/moderate CAA 6 5
Newcastle 78 M 37 CAA/moderate CAA 6 5
Newcastle 90 F 90 CAA/moderate CAA 6 5
Newcastle 87 M 22 CAA/moderate CAA 6 5
Newcastle 81 M 43 CAA/moderate CAA 2 0
Newcastle 86 M 44 CAA/moderate CAA 3 4
Newcastle 62 M 28 CAA/moderate CAA 6 5
Newcastle 78 M 17 CAA/moderate CAA 6 5
Newcastle 73 F 47 CAA/severe CAA 4 3
Newcastle 79 M 13 CAA/severe CAA 3 4
Newcastle 86 F 51 CAA/severe CAA 6 5
Newcastle 86 F 47 CAA/severe CAA 6 5
Newcastle 73 M 7 CAA/severe CAA 6 5
Newcastle 76 F 37 CAA/severe CAA 6 5
Newcastle 78 M 18 CAA/severe CAA 6 5
Newcastle 77 M 78 CAA/severe CAA 6 5
Shefffield 84 F 36 White matterhyperintensity
Shefffield 78 F 47 White matterhyperintensity
Shefffield 91 F 35 White matterhyperintensity
Shefffield 91 F 36 White matterhyperintensity
Shefffield 89 M 46 White matterhyperintensity
Shefffield 87 F 17 White matterhyperintensity
4.2. Assessment of AQP4 Expression by Immunohistochemistry
All groups were qualitatively and quantitatively assessed for AQP4 and qualitatively assessed for
GFAP. AQP4 was both qualitatively and quantitatively assessed in all disease states using anti-aquaporin
4 (rabbit polyclonal, 1:200;, Santa Cruz Biotechnology, Dallas, TX, USA). We also qualitatively assessed
astrocytes using anti-GFAP in all disease states (rabbit polyclonal, 1:500; Agilent Dako, Santa Clara,
CA, USA), a marker for the intermediate filament glial fibrillary acidic protein. All washing steps
were performed three times for 5 min using 0.01M PBS pH 7.4. Sections of 10 µm thickness were
first deparaffinised and then rehydrated through a graded series of alcohols. Endogenous peroxidase
activity was quenched with 3% hydrogen peroxide for 15 min. Heat mediated antigen retrieval was then
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performed by microwaving in ethylenediaminetetraacetic acid (EDTA) buffer (pH 8.0). Sections were
then incubated in a blocking solution consisting of phosphate buffered saline (PBS) with 0.1% triton
and 15% normal goat serum for 1 h prior to incubation with primary antibody. Slides were incubated
overnight with anti-aquaporin 4 or anti-GFAP at 4 ◦C. After washing with PBS, slides were incubated
with goat anti-rabbit IgG (1:400; Vector). Sections were washed with PBS and incubated with ABC
(Vector) for 1 h. AQP4 or anti-GFAP immunoreactivity was visualised by incubating tissue sections in
glucose oxidase diaminobenzidine nickel solution for 5 min. Sections were then washed, dehydrated,
cleared in xylene and coverslipped with DPX (Thermo Fisher Scientific, Loughborough, UK).
Tissue sections were examined using an Olympus dot slide microscope. Five non-overlapping
regions of interest of 1mm2 were captured from the cortical grey matter and underlying white matter
from each tissue section. The five regions of interest were adjacent and were selected from similar
locations in all cases and the investigator was blinded to the nature of the cases. Image J software
(National Institutes of Health) [59] was used to calculate percentage area stained for AQP4 from
each image.
4.3. Assessment of AQP4 and CAA Severity by Immunofluorescence
The relationship of AQP4 expression to astrocytes and blood vessels in the presence of CAA
pathology was qualitatively assessed in all disease states using immunofluorescence and confocal
microscopy. Sections were first deparaffinised and then rehydrated through a graded series of alcohols.
The following antigen retrieval methods were used, depending on the primary antibody: heat mediated
antigen retrieval by microwaving in EDTA buffer (pH 8.0) (for anti-aquaporin 4); 5 min, 1 mg/mL
pepsin dissolved in 0.2 M hydrochloric acid at 37 ◦C (for anti-collagen IV) and 3 min 98 % formic acid
(for anti-Aβ 4G8). Sections were then incubated in a blocking solution consisting of PBS with 0.1%
Triton and 15% normal goat serum for 1 h prior to incubation with primary antibody. Slides were
incubated overnight with the appropriate antibody combination: anti-aquaporin 4 (rabbit polyclonal,
1:200; Santa Cruz), anti-GFAP (mouse monoclonal, 1:100, Proteintech, Manchester, UK), anti-Aβ 4G8
(mouse monoclonal, 1:100, Biolegend, San Diego, CA, USA) and anti-collagen IV (mouse monoclonal,
1:100, Abcam, Cambridge, UK) at 4 ◦C. After washing with PBS, slides were incubated in appropriate
fluorescently labelled secondary antibodies (1:200, (Thermo Fisher Scientific, Loughborough, UK). for 1
h at room temperature. Control experiments were performed by omitting the primary antibodies and
by using isotype controls for the monoclonal antibodies. Sections were washed and incubated with
Sudan Black (Sigma-Aldrich, Dorset, UK, 1% in 70% alcohol) for 3 min to quench autofluorescence,
before being washed and coverslipped with Mowiol (Sigma-Aldrich, Dorset, UK).
Three tissue sections of 10 µm thickness per case were viewed with a Leica TCS SP8 laser scanning
confocal microscope and a 63× objective. 660 µm2 Z-stack images of cortical grey matter and underlying
white matter (×5) were captured from each tissue section. Fluorescent channels were obtained in series,
followed by an overlay image of both channels. These images were viewed using Leica Application
Suite X software (version 3.4, Leica Microsystems, Milton Keynes, UK).
4.4. Statistical Analysis
The investigator was blinded to the true identity of disease state. The data were summarised by
disease state using median with lower and upper quartiles, but for cross-referencing purpose with
the results in the later analyses, mean with standard deviation were also presented and interpreted.
Kruskall–Wallis non-parametric test was performed followed by Mann–Whitney U tests to determine
which disease state were significantly different regarding the two outcomes. The parametric equivalent
(one-way ANOVA and two-sample t test) were also performed for cross-referencing purpose. Bonferroni
correction was applied for all multiple comparisons. The two outcomes were compared within each
disease state using the paired sample t test as the difference between the two outcomes was normally
distributed. The Braak stages for neurofibrillary pathology data were available only in the old
non-demented, moderate and serve CAA brains. The relationship between Braak stage and disease
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state was assessed using Spearman’s rank correlation. Univariate linear regression analysis was
performed on the old non-demented and CAA brains to test for statistical significant differences in
percentage area stained for AQP4 separately in grey and in white matter between disease states,
Braak stages, age and sex. Adjusted linear regression models were also developed with all 4 covariates,
also with disease states and Braak stages only. The same univariate and adjusted regression models were
also presented but using the severe CAA group as reference category instead of the old non-demented
group to provide results from all three pairwise comparisons. All p values presented are referenced at
the 5% significance level, and in the case of multiple comparisons between groups, an appropriate new
threshold for statistical significance is stated using the Bonferroni correction method. All statistical
analyses were performed using IBM SPSS Statistics version 25.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/4/1225/
s1.
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